The stock was +4% today (investors like cost-cutting); however, the stock is -64% from its Jan 2020 high and an astonishing -91% from its all-time high in Jan 2014.
Ocaliva sales in PBC will probably put a floor under the share price, but the chance of Ocaliva being resurrected for NASH is close to nil, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”